Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
Completed
Helsinn Healthcare SA
Phase 2
2006-03-01
The primary purpose of this study is to explore the efficacy of three different dose
schedules of palonosetron for the prevention of emesis over a 7-day study interval in
multiple myeloma patients.
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
Completed
Eisai Inc.
Phase 2
2006-03-01
The primary purpose of this study is to explore the efficacy of three different dose
schedules of palonosetron for the prevention of emesis over a 7-day study interval in
multiple myeloma patients.
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Completed
Heron Therapeutics
Phase 3
2006-06-01
This randomized phase III trial is studying APF530 and dexamethasone to see how well they
work compared with palonosetron and dexamethasone in preventing nausea and vomiting in
patients receiving chemotherapy for cancer.
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
Completed
National Cancer Institute (NCI)
N/A
2006-01-01
RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and
palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by
chemotherapy.
PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron
hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in
patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast
cancer
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
